A 2-Part, Randomized, Double Blind and Open-Label, Placebo and Active-Comparator Controlled Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics for TAK-906 in Subjects With Diabetes Mellitus and Gastroparesis or With Idiopathic Gastroparesis

Trial Profile

A 2-Part, Randomized, Double Blind and Open-Label, Placebo and Active-Comparator Controlled Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics for TAK-906 in Subjects With Diabetes Mellitus and Gastroparesis or With Idiopathic Gastroparesis

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs TAK 906 (Primary) ; Metoclopramide
  • Indications Gastroparesis
  • Focus Adverse reactions
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 13 Mar 2018 Status changed from active, no longer recruiting to completed.
    • 06 Mar 2018 Planned End Date changed from 9 Mar 2018 to 10 Mar 2018.
    • 06 Mar 2018 Planned primary completion date changed from 9 Mar 2018 to 10 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top